Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data
Christine L Baker,1 Kelly H Zou,1 Jun Su2
1Pfizer Inc., New York, NY, USA; 2Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
Background: Treatment of stable chronic obstructive pulmonary disease (COPD) with long-acting bronchodilator (LABD) medications is recommended by the 2014 Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines. The primary objective of this study was to examine LABD prescription fills after a COPD-related hospitalization.
Methods: This retrospective observational study used claims from Truven Health MarketScan® Commercial and Medicare Supplemental databases. Patients (age ≥40, commercial; age ≥65, Medicare supplemental) had a first hospitalization with a primary COPD diagnosis between April 1, 2009 and June 30, 2011 (index hospitalization) and were continuously enrolled for 1 year before and 9 months after hospitalization. Patients were categorized according to pre-index and/or post-index pharmacy claims.
Results: A total of 27,738 patients had an index hospitalization and met inclusion/exclusion criteria. Of those, 19,783 patients had COPD as a primary or secondary diagnosis during the year before index hospitalization and were included in the analysis. Approximately one quarter of the patients (26.32%) did not fill a prescription for an LABD or short-acting bronchodilator both 90 days before and 90 days after hospitalization. During the 90-day pre-index period, 40.57% of patients filled an LABD (with or without a short-acting bronchodilator) prescription. Over half of the patients (56.88%) filled an LABD prescription at some point during the 180-day post-index period, but, of those, a significantly greater proportion of patients filled an LABD prescription in the 1- to 90-day post-index period than in the 91- to 180-day post-index period (51.27% versus 43.66%; P<0.0001).
Conclusion: A significant proportion of COPD patients in this study did not fill an LABD prescription before hospitalization for COPD. Moreover, hospitalization did not appear to greatly impact LABD initiation. Lastly, patients who did not fill an LABD prescription within the first 90 days posthospitalization were not likely to fill an LABD prescription later. Taken together, the results of this study suggest that many patients with COPD are undertreated.
Keywords: chronic obstructive pulmonary disease, non-interventional, retrospective, short-acting bronchodilator
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
Baker CL, Zou KH, Su J
Published Date: 12 November 2013
Readers of this article also read:
Ongel EA, Karakurt Z, Salturk C, Takir HB, Burunsuzoglu B, Kargin F, Ekinci GH, Mocin O, Gungor G, Adiguzel N, Yilmaz A
Published Date: 17 October 2014
Finney LJ, Ritchie A, Pollard E, Johnston SL, Mallia P
Published Date: 13 October 2014
Health status in patients with coexistent COPD and heart failure: a validation and comparison between the Clinical COPD Questionnaire and the Minnesota Living with Heart Failure Questionnaire
Berkhof FF, Metzemaekers L, Uil SM, Kerstjens HAM, van den Berg JWK
Published Date: 22 September 2014
Once-daily indacaterol 75 µg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S
Published Date: 1 September 2014
Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K
Published Date: 27 August 2014
Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD
Moraes MR, da Costa AC, Corrêa KS, Junqueira-Kipnis AP, Rabahi MF
Published Date: 29 July 2014
A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial–mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study
Sohal SS, Soltani A, Reid D, Ward C, Wills KE, Muller HK, Walters EH
Published Date: 27 May 2014
Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease
Wang XR, Li YP, Gao S, Xia W, Gao K, Kong QH, Qi H, Wu L, Zhang J, Qu JM, Bai CX
Published Date: 27 May 2014
Woods JA, Wheeler JS, Finch CK, Pinner NA
Published Date: 3 May 2014
Anemia and health performance score evaluation as decisive factors for noninvasive mechanical ventilation decisions in AECOPD: are there new key cornerstones?
Esquinas AM, Confalonieri M
Published Date: 30 January 2014